^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tevimbra (tislelizumab-jsgr)

    i
    Other names: BGB-A317, BGB A317, VDT482, BGBA317, VDT 482, VDT-482
    Company:
    BeOne Medicines
    Drug class:
    PD1 inhibitor
    Related drugs:
    1m
    Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Tang-Du Hospital
    New P2 trial
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    1m
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=160, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    1m
    A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, West China Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gilotrif (afatinib) • Tevimbra (tislelizumab-jsgr)
    1m
    Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases (clinicaltrials.gov)
    P3, N=332, Not yet recruiting, Peking University
    New P3 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    1m
    Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients (clinicaltrials.gov)
    P1, N=12, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting | Trial completion date: Feb 2026 --> Feb 2027
    Enrollment open • Trial completion date
    |
    cisplatin • gemcitabine • Tevimbra (tislelizumab-jsgr)
    1m
    A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, West China Hospital
    New P1 trial
    |
    Tevimbra (tislelizumab-jsgr)
    1m
    A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. (clinicaltrials.gov)
    P2, N=98, Completed, West China Hospital | Recruiting --> Completed
    Trial completion
    |
    Gilotrif (afatinib) • Tevimbra (tislelizumab-jsgr)
    1m
    Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. (PubMed, Curr Med Res Opin)
    In the RATIONALE-305 trial, first-line tislelizumab + chemotherapy (CAPOX ([capecitabine + oxaliplatin] or 5-fluorouracil [5-FU] + cisplatin) significantly improved overall and progression-free survival (PFS) versus placebo + chemotherapy in unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC). This exploratory analysis evaluated the comparative efficacy of tislelizumab + CAPOX versus tislelizumab + CAPOX or FOLFOX (5-FU, leucovorin, oxaliplatin) using a matching-adjusted indirect comparison (MAIC) approach...Although median PFS was numerically longer with the mixed chemotherapy backbone, these findings are exploratory in nature and warrant further investigation. ClinicalTrials.gov, RATIONALE-305 (NCT03777657); DisTinGuish (NCT04363801).
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium
    1m
    Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review. (PubMed, Front Immunol)
    This is the first reported case of successful eculizumab rescue treatment for probable tislelizumab-related MMM overlap syndrome with dual seropositivity. Our finding suggests eculizumab may represent a promising rescue option for ICI-MMM warranting prospective evaluation.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TTN (Titin)
    |
    Tevimbra (tislelizumab-jsgr)
    1m
    First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial. (PubMed, J Clin Oncol)
    First-line disitamab vedotin with tislelizumab and S-1 demonstrated remarkable antitumor activity and a manageable safety profile in HER2-overexpressing advanced G/GEJ adenocarcinoma, warranting validation in randomized controlled trials.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 overexpression
    |
    Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin)
    1m
    BGB-A317-15025-101: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=157, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • BGB-15025
    1m
    A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=570, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010